MediBeacon Kidney Monitor

MediBeacon Kidney Monitor

The Challenge

MediBeacon came to FutureBrand Speck with their first product platform, a transdermal GFR monitor. The innovative system offers real-time, easy-to-use, and cost-effective monitoring of kidney function. MediBeacon’s noninvasive monitoring technology allows for earlier detection of renal issues enabling clinicians to provide earlier, and hence more effective interventions. The technology needed to be low cost and straightforward to integrate into existing ICU rooms and workflows. In order to design a clear and appropriate interface, it was also crucial to understand how intensive care nurses would place the sensor on patients, administer the reagent, and interact with critical care patients.

MediBeacon Kidney Monitor

The Solution

Stakeholder workshops, workflow journey mapping and ethnographic insights helped us dive into the behaviors and inner workings of the ICU.

In terms of the device’s optical sensor, we focused on understanding skin adhesives and the human factors that relate to correct sensor placement with minimal discomfort and high reliability. After conducting a thorough analysis, Speck made a skin adhesive recommendation, designing the contact patch and sensor surface area with this in mind. The sensor tethers to a pole cart mounted console with a narrow footprint. A large graphic display promotes clear and direct communication of real-time information.  

MediBeacon Kidney Monitor

The Results

Speck’s end-to-end engagement with the client meant that we had visibility into the current ICU experience, the challenges of renal monitoring, human factors elements relating to sensors, consoles, and reagents, and the information needs of ICU healthcare providers. By extracting information from multiple channels and “touching” multiple elements of the product, we helped MediBeacon develop an aesthetically pleasing, visually integrated, and straightforward device experience to support doctors and nurses who are working with matters of life and death.

The design is public and moving forward into engineering for clinical trials. 

Capabilities involved